Friday, 18 Aug 2017

You are here

The RheumNow Week in Review – 24 February 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

  1. Study of >43K Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis patients show a 14-34% increase risk for depression; but not for suicide or suicidal ideation. http://buff.ly/2lBwMb2
  2. Scleroderma Renal Crisis Criteria include HTN, Acute Kidney Injury, encephalopathy, seizures, microangiopathic hemolytic anemia https://t.co/J957AxYYGX
  3. 183 SLE Patients in a Phase II trial showed no benefit with IL-6 inhibition(PF-04236921) for 6 mos. The highest dose was D/C for safety. https://t.co/PdAZ0Petxs
  4. #RWCS17 Dr Bergman shows incredibly poor adherence to drug therapy. Suggests you need time and a plan to combat https://t.co/mLUzlsqUet
  5. Analysis 26 studies failed to show any predictors of mycohenolate mofetil responses in Lupus. More research needed. https://t.co/HwjhoLTS5
  6. Metanalysis shows no Cancer risk with Inflx (OR 1.68), ETN (0.79), ADA (0.93), ABA (1.04), RTX (0.58), TCZ (0.60), Tofa (1.15) https://t.co/TQp4AOAmuL
  7. Prior Authorizations is a problem for GI docs too - 63% use >25% FTE to do PA and 73% make > 5 calls (37% >10 calls) per day to payors https://t.co/yYSjjcTGwq
  8. CDC reports seasonal Influenza peaked in 2nd week Feb 2017 & will continue for weeks. No antiviral resistance seen thus far. https://t.co/YNMHbdYz1c
  9. Dr Mahadevan #RWCS17 shows data that there is a 1/2000 risk of bone fractures with chronic PPI use https://t.co/hYYWmPD6rE
  10. Dr Mahadevan #RWCS17 shows that PPI chronic use yields a 1/4000 risk of PPI induced C. ridicule diarrhea https://t.co/zIpl8k8DR0
  11. #rwcs2017 Dr Kavanaugh shows RCT where apemilast does well against etanercept in psoriasis. https://t.co/ZQYTdLBLZ9
  12. Dr Kevin Winthrop at #RWCS2017 reviews DMARD/Biologic effects on vaccine responses. Most effected by RTX, least by MTX. https://t.co/un74cCDo04
  13. ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos https://t.co/hb6RdEnWj6
  14. FDA approves the IL-17 inhibitor “Siliq” (brodalumab; from Valeant) for moderate-severe plaque psoriasis.Comes with a black box warning for suicide. https://t.co/rzSOVP1gd3
  15. Baricitinib (trade name “Olumiant” ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo with MTX. https://t.co/7lFqrfL3fF
  16. Higher Hip and Knee Replacement Revision Rates in Younger Patients 
  17. Sirukumab shows moderate efficacy in Rheumatoid Arthritis
  18. Abatacept shows modest efficacy in Giant Cell Arteritis
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review – 18 August 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on lupus survival, pediatric lupus guidelines from SHARE, room temperature storage of etanercept, over or under-testing by rheumatologists and failure of pain meds to treat pain.

The RheumNow Week in Review – 11 August 2017

The RheumNow Week in Review caps the week's news every Friday. Dr Jack Cush reviews the news, journal reports and important events from the past week in rheumatology.  This week's news highlights include new data on the incidence of arthritis, lag times in patient referral, criteria for referral and why/how weather change affects arthritis pain.

Criteria for Early Referrals from Primary Care

Early diagnosis and early intervention has been the mantra of all who manage musculoskeletal (MSK) diseases for decades. While the rules for referral may be clear to some, the lack of uniformity and promotion amongst primary care providers is less certain.

MSK Ultrasound Now Standard for Rheumatology Training

In the United States, musculoskeletal ultrasound (MSUS) in rheumatology has grown significantly in the last few decades. Ten years ago, more than half of rheumatology fellows had training or exposure to MSUS. A current survey of training programs shows that 94% provide MSUS training.

The RheumNow Week in Review – 4 August 2017

Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com.